Metformin and Tadalafil: Is It Safe to Take Them Together?

The Short Answer: Low Risk, But Not Zero Risk

Metformin and tadalafil do not interact through shared liver enzymes or transport proteins in a way that changes blood levels of either drug. Metformin is eliminated almost entirely unchanged by the kidneys via organic cation transporters (OCT1/OCT2) and is not a substrate, inhibitor, or inducer of CYP3A4. Tadalafil is metabolized predominantly by CYP3A4 to an inactive catechol glucuronide and does not meaningfully affect renal OCT transport.

The real concern is pharmacodynamic: both drugs can lower blood pressure. Tadalafil relaxes vascular smooth muscle by inhibiting phosphodiesterase type 5, raising cyclic GMP, and producing systemic vasodilation. Metformin's direct vascular effects are subtler, but evidence from a 2016 meta-analysis in Diabetologia suggests metformin modestly reduces systolic blood pressure (by roughly 1.5 to 2 mmHg) independent of glycemic control, likely through AMPK-mediated endothelial nitric-oxide signaling.

That combination of vasodilation mechanisms is rarely dangerous on its own. It becomes more relevant if you also take an ACE inhibitor, ARB, calcium-channel blocker, or any nitrate compound.

Understanding Each Drug: What It Does in a Woman's Body

Metformin: More Than a Diabetes Drug

Metformin (dimethylbiguanide) is the first-line oral agent for type 2 diabetes in most major guidelines, including the American Diabetes Association Standards of Care. In women's health, it carries a broader role that most general-audience articles miss entirely.

PCOS. Metformin is used in polycystic ovary syndrome to reduce hyperinsulinemia, restore ovulatory cycles, and lower androgen levels. The ASRM and ESHRE 2023 international evidence-based PCOS guideline recommends metformin as an adjunct to lifestyle therapy for metabolic and reproductive outcomes.

Perimenopausal metabolic health. Insulin resistance worsens in perimenopause, driven partly by declining estradiol. Some clinicians prescribe metformin off-label in this life stage to attenuate visceral fat gain and reduce cardiovascular risk, though randomized trial evidence specific to perimenopausal women remains thin (see section on evidence gaps below).

Typical dosing in women. Standard doses range from 500 mg twice daily to 2,550 mg daily in divided doses, titrated over weeks to minimize gastrointestinal side effects. Extended-release formulations reduce nausea substantially. Women tend to reach lower steady-state metformin plasma concentrations than men at the same dose per kilogram of body weight, partly because of sex differences in renal tubular secretion, though clinical dose adjustment by sex is not currently standard practice.

Tadalafil: What Women Are Actually Prescribed It For

Most people think of tadalafil (Cialis, Adcirca, Alyq) as a men's erectile-dysfunction drug. In women's health, the picture is different.

Pulmonary arterial hypertension (PAH). The FDA approved tadalafil 40 mg once daily for PAH (WHO Group 1) under the brand name Adcirca in 2009. PAH disproportionately affects women: approximately 80 percent of idiopathic PAH patients are women, with peak incidence in the reproductive and perimenopausal decades. If you have PAH and are also on metformin for diabetes or PCOS, the combination is clinically common.

Female sexual dysfunction (FSD). Tadalafil is used off-label for female sexual arousal disorder and hypoactive sexual desire disorder (HSDD), particularly in postmenopausal women and in women with diabetes-related genital blood-flow impairment. A 2013 randomized trial in Obstetrics and Gynecology showed modest improvements in Female Sexual Function Index scores compared with placebo, though effect sizes were small and this indication is not FDA-approved. The evidence base is limited and largely extrapolated from male PDE5i trials.

PCOS and endothelial dysfunction. Women with PCOS have measurable endothelial dysfunction. Small investigational studies have explored PDE5 inhibitors to improve uterine and ovarian perfusion, but this remains experimental and is not a standard-of-care use.

The Interaction Mechanism in Detail

Pharmacokinetic Pathway: No Meaningful Overlap

A pharmacokinetic (PK) interaction requires two drugs to compete for the same metabolic enzyme, transporter, or elimination pathway. That competition does not happen here.

Metformin enters cells via organic cation transporter 1 (OCT1) in the gut and liver, and is excreted by OCT2 and multidrug and toxin extrusion proteins (MATE1/MATE2-K) in the kidney. Its renal clearance exceeds glomerular filtration rate, confirming active tubular secretion as the dominant elimination route. CYP enzymes play no role.

Tadalafil is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors such as ketoconazole increases tadalafil AUC by approximately 312 percent; CYP3A4 inducers such as rifampin reduce tadalafil AUC by 88 percent. Metformin does none of this.

Bottom line on PK: neither drug alters the plasma concentration of the other.

Pharmacodynamic Overlap: Where the Risk Lives

The interaction is pharmacodynamic. Both drugs affect blood pressure through distinct but additive vasodilatory pathways.

Tadalafil inhibits PDE5, preventing breakdown of cGMP in vascular smooth muscle, leading to relaxation and vasodilation. This mechanism can cause a mean maximum decrease in systolic blood pressure of 1.6 mmHg when tadalafil is taken alone, rising to a clinically significant drop when combined with antihypertensives or alpha-blockers.

Metformin's vascular contribution is more indirect. It activates AMPK in endothelial cells, which increases endothelial nitric oxide synthase (eNOS) activity, raising NO bioavailability and causing mild vasodilation. Studies in patients with type 2 diabetes show metformin reduces markers of endothelial dysfunction and lowers brachial artery pulse pressure.

When you combine both, you have two drugs nudging blood pressure in the same direction. For most women on stable doses of both agents, this additive effect is minor. The risk climbs in three situations:

1. You are also taking an antihypertensive (ACE inhibitor, ARB, calcium-channel blocker, diuretic, or alpha-blocker).
2. You stand up quickly (orthostatic hypotension).
3. You are dehydrated, for example during illness or heavy exercise.

The Nitrate Rule (Critical Safety Point)

Tadalafil is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite). The FDA label warns that co-administration of tadalafil with nitrates can cause severe and potentially fatal hypotension. Metformin is not a nitrate. This contraindication does not apply to metformin. Some women confuse this warning because the two drug classes share a vascular target (nitric oxide signaling), but the mechanism and magnitude of blood-pressure effect are categorically different.

Who Is Most Likely Taking Both Drugs? A Life-Stage Map

Reproductive Years: PCOS and Fertility

A woman in her 20s or 30s on metformin for PCOS is unlikely to be prescribed tadalafil for standard indications. The scenario where both appear together in this life stage is experimental or investigational. If you are on metformin for PCOS and a provider suggests tadalafil for any reason, ask specifically what FDA-approved or guideline-supported indication they are treating.

Reproductive Years: Pulmonary Arterial Hypertension

PAH can present at any age, including during pregnancy, and the majority of patients are women of reproductive age. A woman with both PCOS-related insulin resistance (on metformin) and PAH (on tadalafil 40 mg daily) is a clinically real and not uncommon patient. The 2022 ESC/ERS Guidelines on Pulmonary Hypertension recommend PDE5 inhibitors, including tadalafil, as part of combination targeted therapy for PAH. In this setting, monitoring blood pressure at each visit and educating the patient about dizziness on standing is standard care.

Perimenopause and Postmenopause: Metabolic and Sexual Health Overlap

Blood pressure rises after menopause. Many postmenopausal women are on metformin for type 2 diabetes or metabolic syndrome and may be offered tadalafil off-label for sexual arousal dysfunction. Postmenopausal women with diabetes have higher rates of sexual dysfunction compared with age-matched women without diabetes, with prevalence estimates above 50 percent in some cross-sectional studies. This is the life stage where the combination is most likely to be encountered in a sexual-health context, and it is also the life stage where baseline blood pressure is often already elevated.

WomanRx Life-Stage Monitoring Framework for Metformin + Tadalafil:

| Life Stage | Most Likely Indication | Key Monitoring Point | |---|---|---| | Reproductive (PCOS) | Metformin for PCOS; tadalafil investigational | Blood pressure; clarify indication | | Reproductive (PAH) | Both drugs as standard therapy | Standing and lying BP at each visit | | Perimenopause | Metformin for metabolic risk; tadalafil off-label FSD | Baseline BP, antihypertensive list review | | Postmenopause | Type 2 diabetes + sexual dysfunction | Orthostatic vitals, dehydration risk |

Sex-Specific Pharmacology: What the Trials Often Miss

Women have been underrepresented in both metformin and tadalafil clinical trials. This is a meaningful evidence gap you deserve to know about.

Most metformin PK studies included predominantly male cohorts. The key renal-clearance data showing that women have approximately 20 to 25 percent lower metformin apparent clearance than men, after adjusting for body weight, comes from a population PK analysis of 393 subjects in the ADOPT trial. That finding has not translated into sex-specific dosing recommendations in FDA labeling, though some pharmacologists argue it should.

Tadalafil trials for erectile dysfunction enrolled no women by design. The PAH trials (PHIRST-1) included mixed-sex populations, but subgroup analyses by sex are limited. The off-label FSD trials are small, short, and do not enroll women with diabetes at sufficient power to draw conclusions about the metformin-tadalafil combination specifically.

The FDA's 2020 Action Plan for the Inclusion of Women in Clinical Trials acknowledges this gap and calls for sex-stratified reporting, but most historical data predates that guidance.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or trying to conceive.

Metformin in Pregnancy and Lactation

Metformin crosses the placenta. Human data show fetal-to-maternal concentration ratios close to 1.0. Despite placental transfer, metformin is used in gestational diabetes and PCOS-related pregnancy complications and is generally not associated with major congenital malformations based on multiple meta-analyses, including a 2020 Cochrane review of gestational diabetes pharmacotherapy. ACOG Practice Bulletin No. 190 on gestational diabetes states that metformin is an acceptable alternative to insulin in women who decline or cannot use insulin, with the caveat that long-term offspring metabolic outcomes require further study.

In breastfeeding, metformin transfers into breast milk at low levels, producing estimated infant doses of less than 0.5 percent of the weight-adjusted maternal dose. Most lactation authorities, including LactMed, consider it compatible with breastfeeding.

Tadalafil in Pregnancy and Lactation

The data here are thin. The FDA label for tadalafil states that animal reproductive studies showed no teratogenicity, but there are no adequate and well-controlled studies in pregnant women. Tadalafil is not listed in any FDA pregnancy category under the old lettering system (it was approved after that system was phased out for newer drugs) and carries a Pregnancy and Lactation Labeling Rule (PLLR) statement indicating insufficient human data.

For women with PAH, pregnancy itself carries serious mortality risk, and the 2018 ESC guidelines on the management of cardiovascular diseases during pregnancy recommend PDE5 inhibitors as an option for PAH in pregnancy under expert center supervision, acknowledging the lack of controlled trial data. This is a complex clinical decision that must be made with a pulmonary hypertension specialist, not managed through telehealth alone.

Lactation data for tadalafil are essentially absent. Until adequate data exist, most clinicians advise against tadalafil during breastfeeding unless the indication (PAH) makes cessation dangerous.

Contraception note: tadalafil is not a teratogen by current evidence, and no mandatory contraception requirement exists for tadalafil as a standalone drug. Women with PAH, however, are counseled strongly to avoid pregnancy because of the high maternal mortality risk associated with PAH in pregnancy, regardless of tadalafil use.

Drug Interactions That Matter More Than This One: Metformin's Full Interaction Profile

Since you are here for metformin drug interactions more broadly, a few interactions carry more clinical weight than the metformin-tadalafil pair.

Iodinated contrast media. Metformin should be held before or at the time of iodinated contrast administration and withheld for 48 hours after, due to risk of contrast-induced nephropathy leading to metformin accumulation and lactic acidosis. The ACR Manual on Contrast Media specifies this protocol.

Inhibitors of OCT2/MATE transporters. Drugs that block renal metformin excretion can raise metformin plasma levels significantly. Cimetidine raises metformin AUC by approximately 40 percent by inhibiting OCT2. Trimethoprim, dolutegravir, and vandetanib carry similar warnings. This class of interaction is pharmacokinetic and can cause lactic acidosis at high metformin concentrations.

Alcohol. Alcohol potentiates metformin-associated lactic acidosis risk and should be limited or avoided, especially in the context of binge drinking or fasting states. Women generally reach higher blood alcohol concentrations at the same dose as men due to lower gastric alcohol dehydrogenase activity and lower total body water.

CYP3A4 inhibitors and tadalafil. For tadalafil specifically: azole antifungals (fluconazole, ketoconazole, itraconazole), HIV protease inhibitors, and erythromycin all raise tadalafil exposure. If you are prescribed any of these while on tadalafil for PAH, your prescriber may need to reduce your tadalafil dose.

Clinical Monitoring: What to Expect and What to Ask

When your prescriber knows you are on both metformin and tadalafil, reasonable monitoring includes:

• Blood pressure check at each visit. Ask for both sitting and standing readings. A drop of 20 mmHg systolic on standing meets the definition of orthostatic hypotension.
• Renal function (eGFR and serum creatinine) every 6 to 12 months on metformin. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and should be used with caution when eGFR is 30 to 45 mL/min/1.73 m². Declining renal function also reduces tadalafil clearance.
• Complete medication list review, specifically for nitrates, alpha-blockers, and antihypertensives. This is the conversation that prevents the rare but serious hypotension event.
• Symptom self-monitoring. Lightheadedness on standing, unusual fatigue, or palpitations within 2 hours of taking tadalafil deserve prompt reporting.

Evidence Gaps: What We Do Not Yet Know

Women deserve transparency here. The following questions remain unanswered by controlled clinical data:

1. Whether sex-specific differences in metformin clearance should prompt dose adjustment in women, particularly older postmenopausal women with lower muscle mass and mildly reduced GFR.
2. Whether tadalafil is effective and safe for female sexual arousal disorder at the doses studied in small trials, and whether the benefit holds specifically in women with diabetes on metformin.
3. Whether PCOS-related endothelial dysfunction responds meaningfully to PDE5 inhibition in a way that improves reproductive outcomes, beyond the vascular biomarker changes seen in small pilot studies.

As WomanRx medical reviewer Dr. Elena Vasquez, MD, notes: "The metformin-tadalafil combination comes up most often in my PAH patients who also have metabolic disease, and in postmenopausal women asking about sexual health options. The pharmacokinetic story is reassuring. The part I spend time on is the full antihypertensive picture, because that is where real blood-pressure drops happen, not from the metformin-tadalafil pair itself."

Who This Combination Is and Is Not Right For

Generally Appropriate (with monitoring)

• Women with type 2 diabetes or PCOS on metformin who are prescribed tadalafil for confirmed PAH
• Postmenopausal women with well-controlled diabetes on metformin who discuss tadalafil with their provider for sexual dysfunction and have no antihypertensive regimen that includes alpha-blockers or nitrates
• Women on stable, low-to-moderate antihypertensive therapy who have had blood pressure checked recently

Requires Extra Caution

• Women also taking alpha-blockers (tamsulosin, doxazosin, prazosin), because tadalafil plus alpha-blockers can cause clinically significant hypotension
• Women with eGFR below 30 mL/min/1.73 m², because both metformin accumulation risk and reduced tadalafil clearance converge
• Women with PAH considering pregnancy, given the high-risk intersection of PAH, pregnancy hemodynamics, and drug safety uncertainty

Not Appropriate

• Women taking any organic nitrate in any form. The tadalafil-nitrate contraindication is absolute and has nothing to do with metformin, but the combination of all three would be dangerous
• Women with severe hepatic impairment (Child-Pugh class C), because tadalafil clearance is severely reduced and metformin's lactic acidosis risk increases